ideasIdea

Print the participation-to-prevalence ratio in every drug label and assessment report

A drug's label should say plainly how well the people in its trials matched the people who get the disease: 'Black patients were 4 percent of participants and 22 percent of cases.' Doctors and patients can then judge how far to trust the result.

Labels and public assessment reports (FDA, EMA EPAR) include a standard representativeness panel: enrolled percentages by race, ethnicity, sex, age band and region beside incidence-based expected percentages, with a participation-to-prevalence ratio per stratum. The panel is machine-readable and aggregated in a public dashboard.

Hypothesis

A visible ratio in the label will increase sponsor effort on representativeness and will be used by guideline committees and payers when weighing evidence for under-represented groups.

Rationale

FDA Drug Trials Snapshots already publish demographics, but separately from the label; placing the comparison in the document clinicians read makes the gap salient at prescribing.

What would test it

Survey clinician and guideline-committee use of the panel after introduction; track change in ratios across approvals over five years.

Maturity

speculative

Who has to act

regulator

Cost to try

Small (under $1M)

Years to first evidence

Bottlenecks it attacks

Trials do not represent the people who get cancer · Older, Black, Hispanic, Asian, rural, poor and multimorbid patients are under-represented, so results may not apply to them.
Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.

Connected

3top

Pages like this

not linked directly; found by shared links

collections

FDA Oncology Approvals (OCE) & Novel Drug Approvals

bottlenecks

Knowledge reaches practice too slowly Trials do not represent the people who get cancer